Premature ejaculation drug delays climax Monday May 23, 1:13 pm ET WASHINGTON (Reuters) - The first drug formulated to treat premature ejaculation delayed climax and increased reported satisfaction in a late-stage study, its developer, Johnson & Johnson (NYSE:JNJ - News), said on Monday. A Phase III clinical trial of 2,614 men showed the drug provided "significant improvements in sexual function, including ejaculatory control, satisfaction with sexual intercourse for men and their partners, and increases in intravaginal ejaculatory latency time," Ortho-McNeil Pharmaceutical, a unit of J&J, said in a statement. The drug, called dapoxetine, is being co-developed by J&J's Alza Corp....
